This inventor holds 3 USPTO granted patents. Top assignee: The Salk Institute. Active years: 1993-1999.
Company Filing History:
Years Active: 1993-1999
Title: Michael Hollmann: Innovator in Glutamate Receptor Research
Introduction
Michael Hollmann is a prominent inventor based in Del Mar, CA (US). He has made significant contributions to the field of glutamate receptor research, holding a total of 3 patents. His work focuses on the electrophysiological and pharmacological properties of glutamate receptors, which are crucial for understanding various neurological processes.
Latest Patents
Hollmann's latest patents include innovative compositions and methods related to glutamate receptors. One of his notable inventions is a patent for glutamate receptor compositions, which discloses novel DNAs that encode proteins characteristic of glutamate receptors. These receptors are exemplified by proteins encoded by representative cDNA clones such as GluR1, GluR2, GluR3, GluR4, GluR5, GluR6, and GluR7. The DNA sequences from these cDNA clones are particularly useful as probes, enabling researchers to identify other members of the L-glutamate receptor family without undue experimentation. Another significant patent involves glutamate receptor antibodies, further emphasizing the importance of these proteins in pharmacological research.
Career Highlights
Michael Hollmann is affiliated with the Salk Institute, a renowned research institution known for its contributions to biological research. His work at the institute has allowed him to explore the complexities of glutamate receptors and their implications in neuroscience.
Collaborations
Hollmann has collaborated with notable colleagues, including James Richard Boulter and Jan Egebejerg Jensen. These collaborations have enriched his research and contributed to advancements in the understanding of glutamate receptors.
Conclusion
Michael Hollmann's innovative work in glutamate receptor research has led to significant advancements in the field. His patents and collaborations reflect his commitment to enhancing our understanding of these critical proteins.